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Abstract Copper accumulation in tissues due to a
biallelic pathogenic mutation of the gene: ATP7B
results in a clinical phenotype known as Wilson disease
(WD). Aberrations in copper homeostasis can create
favourable conditions for superoxide-yielding redox
cycling and oxidative tissue damage. Drugs used in WD
treatment aim to remove accumulated copper and
normalise the free copper concentration in the blood. In
the current study the effect of decoppering treatment on
copper metabolism and systemic antioxidant capacity
parameters was analyzed. Treatment naı¨ve WD patients
(TNWD) (n = 33), those treated with anti-copper
drugs (TWD) (n = 99), and healthy controls (n = 99)
were studied. Both TNWD and TWD patients charac-
terised with decreased copper metabolism parameters,
as well as decreased total antioxidant potential (AOP),
glutathione (GSH) level, activity of catalase, glutathi-
one peroxidase (GPx), and S-transferase glutathione,
compared to controls. TWD patients had significantly
lower copper metabolism parameters, higher total AOP
and higher levels of GSH than TWD individuals;
however, no difference was observed between these
two patient groups with respect to the rest of the
antioxidant capacity parameters. Patients who had
undergone treatment with D-penicillamine or zinc
sulphate did not differ with respect to copper metab-
olism or antioxidant capacity parameters, with the
exception of GPx that was lower in D-penicillamine
treated individuals. These data suggest that anti-copper
treatment affects copper metabolism as well as
improves, but does not normalize, natural antioxidant
capacity in patients with WD. We propose to undertake
studies aimed to evaluate the usefulness of antioxidants
as well as selenium as a supplemental therapy in WD.
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Introduction
Wilson disease (WD; Online Mendelian Inheritance in
Man [OMIM] accession number #277900) is an
autosomal recessive copper storage disease resulting
from biallelic pathogenic mutation in the ATP7B gene,
which encodes the P-type adenosine triphosphatase
(ATPase), ATPase-7B (OMIM number *606882) (Ala
et al. 2007). The physiological functions of ATPase-
7B include the intracellular translocation of copper to
the Golgi apparatus where it is incorporated into
apoceruloplasmin, and the transport of excess copper
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to secretory vesicles for its excretion into the biliary
canaliculi (Terada et al. 1998; Fatemi and Sarkar
2002). In people with pathogenic mutations in both
alleles of ATP7B severe dysfunction of ATP7B results
in excessive copper accumulation primarily in the
hepatocytes and in the brain (Mercer 2001; Petrukhin
et al. 1994; Brewer 2005), thus affected individuals
primarily manifest with hepatic and/or neurological
symptoms that may appear in childhood, adulthood, or
more rarely in the elderly (Brewer 2000; Riordan and
Williams 2001; Ferenci et al. 2007).
Several mechanisms have been proposed to explain
copper-induced cellular toxicity. The basis for most
theories is the ability of copper to participate in the
formation of reactive oxygen species (Lynch and Frei
1993). In the presence of the superoxide anion radical or
other reducing agents, copper2? can be reduced to
copper?, which is capable of catalysing the formation
of hydroxyl radicals from hydrogen peroxide via the
Fenton reaction (Ercal et al. 2001; Gaetke and Chow
2003). Thus, the oxidative stress associated with copper
accumulation may be a central mechanism underlying
the deleterious effects of WD. Some previous reports
have confirmed such hypothesis, including recent
in vitro study on hepatic stellate cells (Xu et al. 2013)
and experimental study on Long-Evans Cinnamon rats
(Yamamoto et al. 2001), as well as clinical studies: one
that enrolled 13 WD children, demonstrating that more
severe liver damage is associated with decreased
antioxidant enzymes in the liver of untreated WD
children (Nagasaka et al. 2006), and another one that
reported a decreased total serum antioxidant capacity in
WD patients (Bruha et al. 2012).
There are few drugs available for the treatment of
WD, including D-penicillamine, trientine, and zinc
salts. D-penicillamine has a free sulfhydryl group,
which functions as a copper chelating moiety. The
major effect of D-penicillamine in WD is to promote
the urinary excretion of copper. Trientine (triethylene
tetramine dihydrochloride) has a polyamine-like
structure that allows copper binding by forming a
stable complex with the four constituent nitrogens in a
planar ring. Like penicillamine, trientine promotes
copper excretion in the urine. The mechanism of
action of zinc salts depends on interfering with the
uptake of copper from the gastrointestinal tract (Ala
et al. 2007; brewer 2005; Roberts and Schilsky 2008).
As anti-copper drugs aim to remove accumulated
copper and normalize the free copper concentration in
the blood to reverse copper poisoning, it may be
hypothesized that such treatment may diminish oxi-
dative stress induced by copper overload among WD
patients. It has been suggested that the antioxidant
profile in tissues or in biological fluids may be helpful
for assessing oxidative stress in humans (Polidori et al.
2001; Ghiselli et al. 2000). Thus, in the current study,
we aimed to evaluate the effect of anti-copper
treatment on systemic antioxidant capacity of WD
patients by comparing the systemic antioxidants, as
well as total antioxidant potential (AOP) between
treatment naı¨ve WD patients (TNWD), patients on
anti-copper treatment with D-penicillamine or zinc
sulphate (TWD), and healthy controls.
Patients and methods
Patients
The clinical and laboratory data for 33 consecutive
patients newly diagnosed with WD who had never
been treated with decoppering drugs (TNWD), as well
as 99 patients who had undergone treatment with anti-
copper drugs (50 with D-penicillamine, 49 with zinc
sulphate; TWD), were evaluated and analysed at the
Second Department of Neurology, Institute of Psy-
chiatry and Neurology in Warsaw, Poland. The
median time of treatment was 48.5 months (IQR
47.0; range: 6–168). All patients met the WD
diagnostic criteria of the 8th International Conference
of Wilson Disease and Menkes Disease (Ferenci et al.
2003). The baseline characteristics of the evaluated
groups of patients are given in Table 1. The control
group included 99 age- and sex-matched healthy
volunteers with a mean age of 35.6 ± 10.5 years, who
did not have a family history of WD, diagnosed liver
disease, neurological or psychiatric disease, chronic
inflammatory disease, or infectious disease. The
control subjects were recruited from hospital staff
and their family. The three most frequent ATP7B
mutations in the Polish population (Gromadzka et al.
2005) were absent in these individuals as documented
by DNA sequence analysis using previously described
methods (Gromadzka et al. 2010).
Blood samples were collected prospectively from
all study subjects for laboratory analysis of oxidative
stress parameters between 2010 and 2012. All groups
of individuals were examined in the same time
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schedule. The biological material was collected as
separated aliquots to be used in individual measure-
ments to avoid repeated freeze–thaw cycles. The
samples were stored at -70 C. The samples were
applied to the assays immediately after thawing to
avoid decrease of enzyme activity. All study partic-
ipants provided written informed consent to partici-
pate in this study. The study protocol was approved by
the local Ethics Committee and conforms to the ethical
guidelines of the 1975 declaration of Helsinki.
Laboratory analyses
Copper metabolism parameters
Serum ceruloplasmin was measured by a colorimetric
enzymatic assay as previously described (Ravin
1961). Serum copper was determined by atomic
adsorption spectroscopy.
Systemic antioxidant capacity and selected small
and large molecule antioxidants
Serum total AOP was evaluated using OxisResearch kit
AOP-450 (cat. no. 21053; Biokom Company, Warsaw,
Poland). The principle of this test depends on the
measuring the reduction potential of the sample that
converts copper2? to copper?, thus changing the ion’s
absorption characteristics. The reduced form of copper
selectively forms a stable 2:1 complex with the
chromogenic reagent with an absorption maximum at
ca. 450 nm. A known concentration of Trolox is used to
create a calibration curve, with the data being expressed
as lM copper reducing equivalents. Serum manganese
superoxide dismutase (MnSOD) activity was investi-
gated using the Superoxide Dismutase Assay Kit (cat.
no. 706002; Cayman Chemical Company; Ann Arbor,
MI, USA) with an assay range of 0.025–0.25 U/mL.
Serum glutathione peroxidase (GPx) activity was
investigated using theGPx Assay Kit (cat. no. 703102;
Cayman Chemical Company) with an assay range of
50.0–344.0 nmol/min/mL. Plasma glutathione S-trans-
ferase (STG) activity was investigated using the
glutathione S-transferase Assay Kit (cat. no. 703302;
Cayman Chemical Company). Serum catalase (Cat)
activity was investigated using the Catalase Assay Kit
(cat. no. 707002; Cayman Chemical Company) with an
assay range of 2.0–35.0 nmol/min/mL. Plasma gluta-
thione (GSH) concentration was investigated using the
Glutathione Assay Kit (cat. no. 703002; Cayman












treatment (n = 99)
Statistics
Male/female
No. of patients 20/13 40/59 v2 4.07; df1;
P \ 0.05
Age
mean ± SD 36.7 ± 11.3 34.9 ± 10.3 P \ 0.40
The clinical form of the WD
No. of patients (%)
Hepatic 15 (45.4) 31 (32.6) v2 0.22; df 1;
P \ 0.65Neurological 18 (54.5) 64 (67.4)
No. of presymptomatic – 4
Decoppering treatment
No. of patients
D-penicillamine (Cuprenil) – 50 –
Zinc sulphate (Zincteral) – 49 –
Duration of treatment (months)
median (IQR) – 48.5 (47.0) –
D-penicillamine (Cuprenil) 42.0 (38.0) P \ 0.08
Zinc sulphate (Zincteral) 58.0 (54.0)
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Statistical analysis
The normality of the analysed continuous variables
was determined using Kolmogorov–Smirnov and
Lilliefors tests. Data were presented as mean and
standard deviation if normally distributed, or median
and interquartile range if the variables were not
normally distributed.
A Student’s t test was used to compare two groups
of normally distributed data.
The Mann–Whitney U-test was used for compar-
isons of variables that were not normally distributed.
Qualitative data are described as ratios with percent-
ages. Comparisons between groups were performed
using the v2 with Yates correction, if appropriate, or
the Fisher exact test when the hypothesis for the v2 was
not fulfilled. Significance was set at P \ 0.05. All
statistical analyses were performed using STATISTI-
CA 10.0 software (StatSoft PL, Cracow, Poland).
Results
Patient characteristics
The mean age of TNWD patients was
36.7 ± 11.3 years, which was not significantly differ-
ent from the age of control subjects (33.5 ± 5.9 years,
P = 0.09). The two groups did not significantly differ
in regards to gender (v2 0.003, df 1, P \ 0.95). The
mean age of TWD patients (34.8 ± 10.3 years) and
their gender was not different from the age and gender
of controls (P \ 0.07; v2 2.26, df 1, P \ 0.07, respec-
tively). TNWD and TWD patients did not differ with
respect to age, but the TWD was group characterized by
a higher prevalence of females (Table 1).
Copper metabolism parameters
TWD and TNWD patients had significantly lower
serum copper and ceruloplasmin levels than controls.
TWD individuals had significantly lower values of
copper metabolism parameters than those from the
TNWD group (Table 2).
Antioxidant capacity parameters
Both TWD and TNWD patients were characterised by
significantly decreased blood levels of total AOP,
GSH, and activity of Cat, GPx, compared to controls.
TNWD patients also had decreased activity of
MnSOD (Table 2). TWD patients had significantly
higher total blood AOP and higher levels of GSH than
TWD individuals; however, no difference was
observed between these two patient groups with
respect to the rest of the antioxidant capacity param-
eters (Table 2).
Copper metabolism, antioxidant capacity
parameters and the type of anti-copper treatment
TWD patients who had undergone treatment with D-
penicillamine or zinc sulphate did not differ with
respect to all antioxidant capacity parameters, with the
exception of GPx that was significantly lower in D-
penicillamine treated individuals (Table 3).
Antioxidant capacity parameters: correlation
to copper metabolism, age at testing and duration
of anti-copper treatment
In TNWD and TWD patients, most antioxidant
capacity parameters did not correlate with copper
metabolism parameters (Table 4). Activity of GPx
negatively or positively correlated with serum copper
and ceruloplasmin in patients receiving zinc sulphate
or D-penicillamine, respectively. MnSOD negatively
correlated with serum copper in the D-penicillamine
treated group. The duration of treatment with zinc
sulphate did not correlate with copper metabolism or
antioxidant capacity parameters (Table 5). A longer
duration of treatment with D-penicillamine correlated
with higher serum ceruloplasmin and higher blood
activity of STG (Table 4).
Discussion
Discoveries over the last few years suggest that
oxidative damage may play an important role in the
pathogenesis of tissue damage in many pathological
conditions, including liver and brain diseases. WD is a
special case characterised by copper storage-induced
progressive liver impairment that in about 40 % of
patients is associated with brain disease. As copper is a
redox active metal, aberrations in its’ homeostasis may
create favourable conditions for superoxide-yielding
redox cycling and oxidative damage to susceptible
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regions within the liver and brain, where easily
oxidised substrates abound (e.g. membrane polyun-
saturated lipids), and redox-based neurochemical
reactions occur. Some previous reports have suggested
that oxidative stress may play an important role in the
pathogenesis of tissue damage in WD (Yamamoto
et al. 2001; Nagasaka et al. 2006; Bruha et al. 2012; Xu
et al. 2013).
Our study evaluated the effect of anti-copper treat-
ment with D-penicillamine or zinc sulphate on copper
metabolism and on systemic antioxidant capacity
parameters in WD patients. Our observations suggest
that copper metabolism disturbance in WD is associated
with significant changes in systemic antioxidant capac-
ity parameters in a direction favouring enhanced
oxidative stress. Moreover, our data suggest that while
anti-copper treatment affects copper metabolism and
improves systemic antioxidant capacity, it does not
normalize it. In the current study TWD patients had
significantly lower copper metabolism parameters,
blood GSH concentrations, activity of the antioxidant
enzymes: Cat, MnSOD, GPx and STG, and total AOP
Table 2 Copper metabolism and antioxidant capacity parameters among WD patients and healthy controls


















































14.4 (5.7) 13.5 (3.6) 12.8 (5.0) a \ 0.270
b \ 0.016
c \ 0.496
Normal ranges: 25.0–45.0 mg/dL for serum ceruloplasmin; 70.0–140.0 lg/dL for serum Cu CREs, lM Cu reducing equivalents
IQR interquartile range; SD standard deviation
*a, P for the comparison between WD patients treatment naive and controls; b, P for the comparison between WD patients on anti-Cu
treatment and controls; c, P for the comparison between WD patients treatment naive and on anti-Cu treatment
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compared with healthy controls (Table 2). The duration
of treatment and copper metabolism parameters did not,
or was only weakly correlated with antioxidant capacity
parameters. TWD individuals had significantly lower
copper metabolism parameters, higher total AOP, and
higher blood GSH, compared with patients who had
never been treated with anti-copper drugs, but no
difference was observed for the remaining antioxidant
capacity parameters (Tables 4, 5).
Our results suggest that patients treated with D-
penicillamine or zinc sulphate do not differ for copper
metabolism parameters nor for most antioxidant
capacity parameters studied. However, patients trea-
ted with D-penicillamine had a significantly lower GPx
activity (57.3 ± 17.0 nmol/min/mL) than those trea-
ted with zinc sulphate (87.6 ± 29.6 nmol/min/mL),
patients treatment naı¨ve (81.9 ± 26.6 nmol/min/mL),
as well as healthy controls (96.1 ± 16.5 nmol/min/
mL) (P \ 0.001 for all the comparisons).
Glutathione peroxidase (GPx is one of the primary
antioxidant enzymes protecting cells against oxidative
stress (Arthur 2000; Brigelius-Flohe´ and Maiorino
2013). It is regarded as a crucial enzyme involved in
reducing damaging hydrogen peroxide and lipid/
phospholipids peroxides (Spallholz 1990; Bor et al.
1999). Impaired activity of GPx may thus result in
membrane lipid peroxidation that is an important factor
contributing to cellular damage (Ku¨hn and Borchert
Table 3 Copper metabolism and antioxidant capacity parameters among WD patients treated with zinc sulphate or D-penicillamine
Parameter Zinc sulphate penicyl (n = 49) D-penicillamine (n = 50) P
Copper metabolism
Serum copper, lg/dL median (IQR) 23.0 (35.0) 21.0 (32.0) \0.787
Serum ceruloplasmin, mg/dL median (IQR) 5.6 (5.5) 5.3 (11.7) \0.649
Antioxidant capacity
Total AOP, CREs mean ± SD 749.7 ± 128.9 795.1 ± 134.2 \0.091
Serum glutathione, lmol/L, median (IQR) 1.2 (1.6) 0.7 (2.4) \0.738
S-transferase glutathione, nmol/min/mL, median (IQR) 15.0 (14.2) 12.3 (13.4) \0.260
Glutathione peroxidase, nmol/min/ml, mean ± SD 87.6 ± 29.6 57.3 ± 17.0 \0.001
Catalase, nmol/min/ml, mean ± SD 142.1 ± 63.2 143.3 ± 76.2 \0.930
Manganese superoxide dismutase, U/ml, median (IQR) 12.3 (5.8) 12.9 (3.2) \0.238
Normal ranges: 25.0–45.0 mg/dL for serum ceruloplasmin; 70.0–140.0 lg/dL for serum Cu
CREs lM Cu reducing equivalents; IQR interquartile range; SD standard deviation
Table 4 Correlation between serum copper and ceruloplasmin and antioxidant capacity in WD patients
Parameter Serum copper Serum ceruloplasmin
Patients
treatment naive
Patients on treatment Patients
treatment naive
Patients on treatment
Zinc sulphate D-penicillamine Zinc sulphate D-penicillamine
Total AOP -0.29 0.03 0.07 0.04 -0.10 -0.02
Glutathione -0.03 0.17 0.05 0.25 0.20 0.17
S-transferase glutathione -0.14 -0.02 0.05 0.10 0.01 0.24
Glutathione peroxidase -0.14 -0.43* 0.34* 0.04 -0.41* 0.36*
Catalase -0.14 -0.08 -0.06 0.14 -0.13 0.08
Manganese superoxide
dismutase
0.04 -0.20 -0.32* 0.32 -0.03 -0.22
Data are shown as correlation coefficients
AOP antioxidant potential
*P \ 0.05
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1987; Ursini and Bindoli 1987). Our observation of
decreased GPx activity in patients treated with D-
penicillamine is in agreement with reports by (Chau-
diere et al. 1984; Chaudiere and Tappel 1984), who
documented that D-penicillamine is a potent in vitro
inhibitor of GPx. It has also been shown that GPx
activity is decreased in vitamin E-deficient chickens
treated with high doses of D-penicillamine (Mercurio
and Combs 1985). Given that in the presence of copper
ions D-penicillamine may undergo auto-oxidation and
produce toxic hydrogen peroxide (Joyce 1991; Starke-
baum and Root 1993), it seems possible that in the
settings of decreased GPx activity, high amounts of
free radicals may be produced via the Haber–Weiss
and Fenton reactions, leading to oxidative cellular
damage. In this context, our observation may supply an
explanation for a wide variety of D-penicillamine
toxicities that had been widely described by Roberts
and Schilsky in (2008).
An important point to address here are possible
therapies that could be used to reverse the effect of D-
penicillamine on GPx activity. In this regard, dietary
supplementation with selenium may protect patients
from this particular side effect of D-penicillamine
treatment. Selenium is contained within the active
center of GPx, and is necessary for the expression and
activity of this enzyme (Flohe et al. 1973; Roy et al.
2005). Selenium supplementation has been shown to
increase GPx activity in various experimental models
(Sappey et al. 1994; Makropoulos et al. 1996), as well
as in human diseases (Schnabel et al. 2008; Al-Taie
et al. 2003; Bosˇkovic et al. 2011).
Our study has some limitations. Because it was a
clinical study, and not an experimental study, we were
unable to evaluate the effect of different doses of zinc
sulphate or D-penicillamine on antioxidant capacity
parameters. We also did not correlate antioxidant
capacity parameters with changes in the clinical status
of patients—this is something that should be evaluated
prospectively including both short-term as well as
long-term evaluation of antioxidant capacity.
In conclusion, our study suggests that despite anti-
copper treatment, WD patients have abnormalities in
copper metabolism as well as decreased antioxidant
capacity and thus are at increased risk of developing
various pathological conditions related to oxidative
stress. In this regard, molecules with antioxidant
activity (like melatonin, lipoic acid, coenzyme Q10,
vitamin E, vitamin C, N-acetyl cysteine, and others)
may be beneficial as a supplementary treatment in WD
(Bosˇkovic et al. 2011). Future studies aimed to
evaluate the possible usefulness of antioxidants as a
supplemental therapy in this disease are warranted. In
regards to our observation of impaired activity of GPx
in patients treated with D-penicillamine, studies aimed
to assess the possible benefit of dietary supplementa-
tion with selenium should also be performed.
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